Korn Ferry Shares Slip, Strong Quarter Meets Weaker Q2 Earnings Guidance
Korn Ferry Stock falls despite an earnings and sales beat as Q2 adjusted EPS guidance trails estimates.
News
Source-attributed headlines with timestamps and links to the companies and crypto markets they mention.
Latest Coverage
30 headlines
Korn Ferry Stock falls despite an earnings and sales beat as Q2 adjusted EPS guidance trails estimates.
Waste Connections (NYSE:WCN) has outperformed the market over the past 15 years by 1.03% on an annualized basis producing an average annual return of 14.05%. Currently, Waste Connections has a market capitalization of
Dell Technologies plans a $4B bond sale to refinance debt, capitalizing on strong AI server demand and a upgraded annual sales forecast.
MannKind licenses Technosphere GLP-1 tech to Rose Pharma for weight management development.
ATI (NYSE:ATI) has outperformed the market over the past 10 years by 15.93% on an annualized basis producing an average annual return of 29.51%. Currently, ATI has a market capitalization of $28.09 billion. Buying
Hunter Biden’s LAPTOP memecoin crashes 98% within an hour of launch as onchain data reveals insider token distributions before trading began.
Leerink Partners analyst Daniel Clark initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Market Perform rating and announces Price Target of $28.
Leerink Partners analyst Puneet Souda initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Outperform rating and announces Price Target of $4.
Leerink Partners analyst Daniel Clark initiates coverage on Harrow (NASDAQ:HROW) with a Outperform rating and announces Price Target of $45.
SpaceX unlocks 319M insider shares worth up to $47.2 billion on Wednesday. The stock is testing resistance at $150.
Leerink Partners analyst Daniel Clark initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $45.
Filed: 2026-09-09 AccNo: 0001193125-26-386091 Size: 170 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Live Nation Entertainment (NYSE:LYV) has outperformed the market over the past 15 years by 9.0% on an annualized basis producing an average annual return of 22.05%. Currently, Live Nation Entertainment has a market
Robinhood Markets has partnered with Crypto.com to route select football event contracts to OG.com's CFTC-regulated exchange, beginning September 8, 2026. The deal comes as prediction markets have become Robinhood's fastest-growing business, generating $156 million in Q2 2026 revenues—surpassing equities and crypto revenues. With football seasons and 2026 midterm elections ahead, the expanded exchange network is expected to enhance liquidity and drive further growth, though regulatory uncertainty and intensifying competition from Interactive Brokers and Coinbase remain headwinds.
SoundHound AI (SOUN) has an average brokerage recommendation of 1.75 (Strong Buy/Buy) with five of eight firms rating it Strong Buy. However, the article cautions that brokerage recommendations often have positive bias due to vested interests. The company's Zacks Rank #2 (Buy) rating is based on a 21.8% increase in consensus earnings estimates over the past month, suggesting analyst optimism about near-term price appreciation.
Bitcoin yield strategies have significantly compressed, with basis trades falling below Treasury rates since February 2026 and incentive-driven BTCfi TVL declining 74% from peak. The market is maturing with institutional products like BlackRock's BITA and Goldman Sachs' acquisition of NEOS Investments, shifting focus from highest rates to rates that fit individual holder profiles and tax situations.
The article recommends two Dividend Kings—Johnson & Johnson and AbbVie—as defensive dividend stocks that can provide steady income during market volatility. Both companies have demonstrated consistent dividend growth and strong business fundamentals in their pharmaceutical and healthcare portfolios.
Lam Research (LRCX) has an average brokerage recommendation of 1.51 (Strong Buy/Buy) from 34 firms, with 67.7% Strong Buy ratings. However, the article cautions that brokerage recommendations often have positive bias due to institutional vested interests. The company's Zacks Rank #2 (Buy) rating is based on a 0.1% increase in consensus earnings estimates over the past month to $9.33, suggesting modest analyst optimism about near-term price movements.